Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 195.84 points (-1.1%) at 17,191 as of Wednesday, Jan. 28, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 821 issues advancing vs. 2,309 declining with 78 unchanged.

The Drugs industry as a whole closed the day down 1.9% versus the S&P 500, which was down 1.3%. Top gainers within the Drugs industry included Celsus Therapeutics ( CLTX), up 4.2%, Cyanotech ( CYAN), up 2.0%, IntelliPharmaCeutics International ( IPCI), up 1.8%, Cormedix ( CRMD), up 3.1% and Pfenex ( PFNX), up 3.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Pfenex ( PFNX) is one of the companies that pushed the Drugs industry higher today. Pfenex was up $0.24 (3.5%) to $7.10 on average volume. Throughout the day, 22,004 shares of Pfenex exchanged hands as compared to its average daily volume of 26,100 shares. The stock ranged in a price between $6.93-$7.30 after having opened the day at $7.02 as compared to the previous trading day's close of $6.86.

Pfenex has a market cap of $136.7 million and is part of the health care sector. Shares are down 6.5% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Cormedix ( CRMD) was up $0.07 (3.1%) to $2.31 on heavy volume. Throughout the day, 185,619 shares of Cormedix exchanged hands as compared to its average daily volume of 73,500 shares. The stock ranged in a price between $2.25-$2.40 after having opened the day at $2.25 as compared to the previous trading day's close of $2.24.

Cormedix has a market cap of $49.9 million and is part of the health care sector. Shares are up 16.8% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IntelliPharmaCeutics International ( IPCI) was another company that pushed the Drugs industry higher today. IntelliPharmaCeutics International was up $0.04 (1.8%) to $2.21 on light volume. Throughout the day, 37,568 shares of IntelliPharmaCeutics International exchanged hands as compared to its average daily volume of 61,200 shares. The stock ranged in a price between $2.04-$2.25 after having opened the day at $2.10 as compared to the previous trading day's close of $2.17.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. IntelliPharmaCeutics International has a market cap of $50.7 million and is part of the health care sector. Shares are down 4.0% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate IntelliPharmaCeutics International a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates IntelliPharmaCeutics International as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on IPCI go as follows:

  • IPCI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 46.75%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • INTELLIPHARMACEUTICS INTL has improved earnings per share by 30.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INTELLIPHARMACEUTICS INTL reported poor results of -$0.56 versus -$0.36 in the prior year. This year, the market expects an improvement in earnings (-$0.19 versus -$0.56).
  • Compared to other companies in the Pharmaceuticals industry and the overall market, INTELLIPHARMACEUTICS INTL's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has increased to -$1.43 million or 20.12% when compared to the same quarter last year. In addition, INTELLIPHARMACEUTICS INTL has also vastly surpassed the industry average cash flow growth rate of -40.76%.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 18.4% when compared to the same quarter one year prior, going from -$2.05 million to -$1.67 million.

You can view the full analysis from the report here: IntelliPharmaCeutics International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.